Composition containing NAD for preventing and treating obesity or impaired glucose tolerance

A technology for nicotinamide adenine and impaired glucose tolerance, which is applied in the fields of medical preparations containing active ingredients, drug combinations, food science, etc. and the effect of treating impaired glucose tolerance, inhibiting weight gain, and increasing exercise capacity

Active Publication Date: 2018-03-27
UNIV OF ULSAN FOUND FOR IND COOPERATION
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no results have been reported on the administration of nicotinamide adenine dinucleotide itself for the treatment of obesity and type 2 diabetes at the animal level

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing NAD for preventing and treating obesity or impaired glucose tolerance
  • Composition containing NAD for preventing and treating obesity or impaired glucose tolerance
  • Composition containing NAD for preventing and treating obesity or impaired glucose tolerance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Experimental materials and methods

[0063] 1-1 Experimental animals

[0064] Mature male C57BL / 6 mice were purchased from Orientbio (Gyeonggi-do, Korea). Unless otherwise stated, mice were given ad libitum access to a standard diet (Agricultural Standard Purina, Seoul, Korea). To make a diet-induced obesity (DIO) model, mice were fed a high-fat diet (60% fat, Research Diet Co., New Brunswick, NJ) for 20 weeks. Animal feeding was carried out under the adjusted temperature (22±1° C.) and a 12-hour light-dark cycle (light conditions from 08:00 a.m to 8:00 p.m).

[0065] For the experiment of single administration of nicotinamide adenine dinucleotide and nicotinamide mononucleotide, nicotinamide adenine dinucleotide (purchased from Sigma, 0.3 mg / kg, 1mg / kg and 3mg / kg) or nicotinamide mononucleotide (purchased from Sigma, 30mg / kg, 100mg / kg and 300mg / kg) after fasting at night to 9-10 am . For long-term nicotinamide adenine dinucleotide therapy, nicotinamide adenine di...

Embodiment 2

[0080] Effects of administration of nicotinamide adenine dinucleotide on food intake and body weight in obese animal models

[0081] To determine the amount of nicotinamide adenine dinucleotide in animals that were induced to become obese by dietary intake, C57BL / 6 mice fed a high-fat diet (HFD) or normal diet (ND) were fed at week 20, Plasma and hypothalamus were collected for high performance liquid chromatography (HPLC, high performance liquid chromatography) for the determination of nicotinamide adenine dinucleotide ( figure 1 ). Compared with the mice fed the normal diet, the mice fed the high-fat diet for 20 weeks showed a significant decrease in the amount of nicotinamide adenine dinucleotide in both plasma and hypothalamus (P<0.05).

[0082] In order to examine the effect of administration of nicotinamide adenine dinucleotide on the food intake of obese animal models, nicotinamide adenine dinucleotide was intracerebroventricularly or intraperitoneally administered, an...

Embodiment 3

[0089] Effects of administration of nicotinamide adenine dinucleotide on physical activity in an animal model of obesity

[0090] In order to test the effect of chronic intraperitoneal injection of nicotinamide adenine dinucleotide (0.3mg / kg / day) on the exercise of obese animal models, these mice were divided into the group of intraperitoneal injection of normal saline ingestion of normal diet, ingestion of Three groups, the high-fat diet intraperitoneal injection of normal saline group and the high-fat diet intraperitoneal injection of nicotinamide adenine dinucleotide group, were evaluated for exercise performance. The amount of physical activity of the normal control group injected with normal saline and ingested a normal diet was significantly higher at night (equivalent to the daytime of humans) than in the daytime, and thus a significant diurnal cycle rhythm of the amount of physical activity was observed. On the contrary, the obese group ingesting a high-fat diet admini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition containing nicotinamide adenine dinucleotide (NAD) as an active ingredient for preventing and treating obesity or impaired glucose tolerance, a food composition, and a method for preventing and treating obesity or impaired glucose tolerance using the same. The NAD of the present invention remedies an abnormal food intake pattern of an obese animal model induced by the intake of a high-fat diet and increases mobility, thereby exhibiting an effect of suppressing the weight increase due to the high-calorie intake and also showing an effect of improving glucose tolerance. In addition, it was verified that the NAD of the present invention is capable of maintaining the above effects with even a much smaller quantity than an NAD precursor known in the prior art. Therefore, the composition containing NAD of the present invention can be favorably used as a pharmaceutical composition or a food composition capable of effectively preventing and treating obesity or impaired glucose tolerance.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing and treating obesity or impaired glucose tolerance containing nicotinamide adenine dinucleotide (NAD, nicotinamide adeninedinucleotide) as an active ingredient, a food composition, and a drug for obesity or impaired glucose tolerance using the same Prevention and treatment methods. Background technique [0002] In oxidation or reduction metabolic reactions, nicotinamide adenine dinucleotide (NAD+, nicotina midedenine dinucleotide) acts as an enzyme cofactor (enzyme cofactors) mediating hydrogen transfer (Berger, F., et al. (2004 )."The new life of a centenarian: signaling functions of NAD+(P)."Trends in biochemical sciences 29(3):111-118). Nicotinamide adenine dinucleotide (NAD+) in the glycolytic reaction (glycolytic reaction) catalyzed by glyceraldehyde 3-phosphate dehydrogenase (glyceraldehyde 3-phosphate dehydrogenase) and the four phases of the tricarboxylic acid (TCA, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7084A23L33/10A61K9/00
CPCA61K9/0019A61K31/7084A23L33/13A61P3/04A61K9/0053
Inventor 金旼宣
Owner UNIV OF ULSAN FOUND FOR IND COOPERATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap